Danaher Corporation (NYSE:DHR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Danaher Corporation (NYSE:DHR) have received an average rating of “Moderate Buy” from the twenty-five brokerages that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and twenty have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $252.3182.

DHR has been the topic of a number of research analyst reports. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on Danaher from $270.00 to $275.00 and gave the stock an “overweight” rating in a research note on Thursday. Jefferies Financial Group raised their target price on shares of Danaher from $255.00 to $265.00 and gave the stock a “buy” rating in a report on Wednesday. Evercore ISI reiterated an “outperform” rating and issued a $254.00 price target on shares of Danaher in a report on Wednesday. Finally, Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd.

Danaher Trading Down 0.4%

Shares of NYSE DHR opened at $218.82 on Monday. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The firm has a market capitalization of $154.56 billion, a P/E ratio of 43.42, a P/E/G ratio of 2.95 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The company’s 50 day simple moving average is $230.60 and its 200 day simple moving average is $214.25.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The business had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, analysts predict that Danaher will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Friday, December 26th were issued a $0.32 dividend. The ex-dividend date was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 25.40%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director directly owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 30,248 shares of company stock worth $6,609,663. Insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Danaher

Institutional investors and hedge funds have recently modified their holdings of the stock. JPL Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter worth about $25,000. Elevated Capital Advisors LLC bought a new position in shares of Danaher during the fourth quarter worth approximately $26,000. WFA of San Diego LLC acquired a new stake in shares of Danaher in the second quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new stake in shares of Danaher in the second quarter valued at approximately $27,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Danaher during the third quarter worth approximately $27,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.